It's been a quick rise to the top for Innovative BioTherapies. The University of Michigan spin-off started with just its founder, U-M Prof. David Hume, in 2003 and now employs 16 people with plans to hire a couple more.
The firm specializes in bio-artificial kidneys, which have been used extensively in combat operations in Iraq. Field hospitals use the technology to help provide quick relief for kidneys, helping to prevent septus and kidney failure while doctors work their magic.
The combination of polymers, cells and biomaterials could also have applications in every day medicine with possible applications for diabetes patients. Innovative BioTherapies is looking into exploring those possibilities but company spokeswoman Deb Buffington says the diabetes angle is still years away from becoming reality.
In the meantime, the company has increased its research staff, hiring one former Pfizer employee and possibly adding another in the near future.
Source: Deb Buffington, vice president of Innovative BioTherapies
Writer: Jon Zemke
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.